文献速递血液透析通路

vonapanitase促进桡头动静脉瘘通畅与透析使用的随机试验(PATENCY-1)

A randomized trial of vonapanitase (PATENCY-1) to promote radiocephalic fistula patency and use for hemodialysis.
PubMed 文献 · J Vasc Surg · 2019-01-01

PATENCY-1是一项双盲安慰剂对照试验,纳入349例拟行桡头动静脉瘘的透析或临近透析患者,313例随机、311例治疗,vonapanitase组210例、安慰剂组103例。主要终点12个月一期通畅率两组无显著差异,但二期通畅率及透析使用率显著提高。

要点

  • vonapanitase未显著改善桡头动静脉瘘12个月一期通畅率。
  • vonapanitase组12个月二期通畅率及透析使用率显著高于安慰剂组。
  • 研究提示vonapanitase可能促进瘘管成熟与使用,需进一步研究验证。

核心结论

  • vonapanitase局部应用未显著改善桡头动静脉瘘的一期通畅率,但与二期通畅率和透析使用率提高相关。

研究设计与样本

  • PATENCY-1为双盲、安慰剂对照随机试验,纳入349例透析或临近透析并拟行桡头动静脉瘘的患者,313例随机(vonapanitase组210例,安慰剂组103例),311例接受治疗。
  • 研究药物溶液在瘘管创建后立即局部应用于动脉和静脉10分钟。

临床怎么用

  • 对于拟行桡头动静脉瘘的透析患者,可考虑局部应用vonapanitase以提高二期通畅率和透析使用率,但需权衡一期通畅率无显著改善的结果。

局限性

  • 研究未报告其他局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Arteriovenous fistulas created in patients with chronic kidney disease often lose patency and fail to become usable. This prospective trial evaluated the efficacy of vonapanitase, a recombinant human elastase, in promoting radiocephalic fistula patency and use for hemodialysis. METHODS: PATENCY-1 was a double-blind, placebo-controlled trial that enrolled 349 patients on or approaching hemodialysis and being evaluated for radiocephalic arteriovenous fistula creation. Of these, 313 were randomized and 311 treated. Patients were assigned to vonapanitase (n = 210) or placebo (n = 103). The study drug solution was applied topically to the artery and vein for 10 minutes immediately after fistula creation. The primary and secondary end points were primary patency (time to first thrombosis or corrective procedure) and secondary patency (time to abandonment). Tertiary end points included use of the fistula for hemodialysis, fistula maturation by ultrasound, and procedure rates. RESULTS: The Kaplan-Meier estimates of 12-month primary patency were 42% (95% confidence interval [CI], 35-49) and 31% (95% CI, 21-42) for vonapanitase and placebo (P = .25). The Kaplan-Meier estimates of 12-month secondary patency were 74% (95% CI, 68-80) and 61% (95% CI, 51-71) for vonapanitase and placebo (P = .048). The proportions of vonapanitase and placebo patients were 39% and 25% (P = .035) with unassisted use for hemodialysis and 64% and 44% (P = .006) with unassisted plus assisted use. CONCLUSIONS: Vonapanitase treatment did not significantly improve primary patency but was associated with increased secondary patency and use for hemodialysis. Further research is needed to evaluate these end points.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bleyer AJ, Scavo VA, Wilson SE, et al. A randomized trial of vonapanitase (PATENCY-1) to promote radiocephalic fistula patency and use for hemodialysis. J Vasc Surg. 2019. PMID: 30683197. doi:10.1016/j.jvs.2018.04.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。